http://www.advancededandtech.alberta.ca/media/180891/bioind_george.pdf Some more info on this. For the bored ppl who like to read =)..
Sorry unfortunately a phase III is pretty far off..
Their "early candidate" finished phase I but they're working on an "enhanced version" for phase I by 2010. http://biz.yahoo.com/ccn/081223/200812230504336001.html?.v=1
I wonder if the early candidate was safe but they noticed something that made them want to enhance it...
Yah you can find a animated demo on the drug in theory on youtube if you search up hepavaxx b. Pretty cool. Been crossing my finger on this company. There was an article with minimal details that i read, it said in there panel of 15 healthy chronic carrier they saw a drastic decrease in viral load. But there test was in combination with interferon injection also. Hopefully the company Paladin Labs that acquired Virexx continue the research and support and heal us all. =D
i've been doing reading on the hepavaxx for over a month since someone else on here mentioned something about it. this has also been mention on the stock market in august. this tactic for all bio companies is used to drive up a stock a bit or generate a little bit of interest hoping for one of the big bio fish to invest into the companies.
these phases are time consuming and they may take years at times.. i was surprised to see you mentioned a 3rd phase completion when only 4 or 5 months ago they finished their first phase.. if true then response to this vaccine is a killing sucess. i'd be very surprised.. happy surprised , that is ..may even invest some money in their stock.. this way i get cured ( God's willing ) and i get rich while at it :-)
here is some info on this vaccine/treatment hepavaxx:
HepaVaxx B
HepaVaxx B Vaccine consists of a recombinant chimeric molecule containing a hepatitis B viral antigen and a portion of a murine monoclonal antibody. The molecule is designed to target dendritic cells, which play a significant role in antigen presentation and initiation of an immune response. In preclinical testing, HepaVaxx B Vaccine has produced both cellular and humoral immune responses. ViRexx believes that the development of humoral and cellular responses may be effective in clearing the virus from patients with chronic hepatitis B infection.